INDP - Indaptus Therapeutics: Advancing Decoy Technology To Address Cancer And Viral Indications
- Indaptus Therapeutics is advancing the Decoy bacteria triggered immune response technology for cancer and viral indications.
- The company was formed from the reverse merger of Intec Pharma and Decoy Biosystems.
- Shares of the company commenced trading on Nasdaq on August 4, 2021.
For further details see:
Indaptus Therapeutics: Advancing Decoy Technology To Address Cancer And Viral Indications